|
|
|
|
LEADER |
03374nam a2200325 u 4500 |
001 |
EB001840204 |
003 |
EBX01000000000000001004193 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
180702 r ||| eng |
245 |
0 |
0 |
|a Diagnosis and management of suspected idiopathic pulmonary fibrosis
|h Elektronische Ressource
|b idiopathic pulmonary fibrosis
|
246 |
3 |
1 |
|a Idiopathic pulmonary fibrosis
|
260 |
|
|
|a [London]
|b National Clinical Guideline Centre
|c 2013, June 2013
|
300 |
|
|
|a 1 PDF file (313 pages)
|
505 |
0 |
|
|a Includes bibliographical references
|
653 |
|
|
|a United Kingdom
|
653 |
|
|
|a Clinical Trials as Topic
|
653 |
|
|
|a Diagnosis, Differential
|
653 |
|
|
|a Idiopathic Pulmonary Fibrosis / diagnosis
|
653 |
|
|
|a Idiopathic Pulmonary Fibrosis / drug therapy
|
653 |
|
|
|a Treatment Outcome
|
710 |
2 |
|
|a National Clinical Guideline Centre for Acute and Chronic Conditions (Great Britain)
|
710 |
2 |
|
|a National Institute for Health and Care Excellence (Great Britain)
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a NICE clinical guidelines
|
500 |
|
|
|a Title from PDF cover. - "Commissioned by the National Institute for Health and Care Excellence."
|
856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK247530
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
082 |
0 |
|
|a 610
|
520 |
|
|
|a Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic interstitial lung disease (ILD) of unknown origin. It is a difficult disease to diagnose and often requires the collaborative expertise of a chest physician, radiologist and histopathologist to reach a consensus diagnosis. Most people with idiopathic pulmonary fibrosis experience symptoms of breathlessness, which may initially be only on exertion. Cough, with or without sputum is a common symptom. Over time, these symptoms are associated with a decline in lung function, reduced quality of life and ultimately death. Specific pharmacological therapies for IPF are limited but the last decade has seen more trials of new drugs which have had a variable impact on clinical practice. A number of difficulties arise when undertaking clinical trials in IPF in terms of defining precise, diagnostic inclusion criteria and clinically meaningful end-points. However, such trials are the only way by which promising new treatments will come to benefit patients. Furthermore, it is only by performing rigorous clinical trials, we have learned that drugs once widely used to treat IPF may in fact have been harmful. The limitations of current pharmacological therapies for IPF highlight the importance of other forms of treatment including lung transplantation and best supportive care such as oxygen therapy, pulmonary rehabilitation and palliation of symptoms. These are interventions which justifiably require scrutiny in the context of healthcare delivery by the modern NHS. Despite the significant burden of disease caused by IPF, there is currently no established framework within the NHS for its diagnosis and management thus creating an environment in which significant variations in clinical care may occur. In recognition of this, the Department of Health commissioned the National Institute of Health and Care Excellence (NICE) to produce a guideline aimed at improving the care of people with IPF.
|